BioVie (BIVI) Competitors $2.77 +0.03 (+1.09%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BIVI vs. TYME, ENLV, AYTU, ADMS, CRVS, ANNX, ALGS, OCS, ABVX, and ATXSShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Tyme Technologies (TYME), Enlivex Therapeutics (ENLV), Aytu BioPharma (AYTU), Adamas Pharmaceuticals (ADMS), Corvus Pharmaceuticals (CRVS), Annexon (ANNX), Aligos Therapeutics (ALGS), Oculis (OCS), ABIVAX Société Anonyme (ABVX), and Astria Therapeutics (ATXS). These companies are all part of the "medical" sector. BioVie vs. Tyme Technologies Enlivex Therapeutics Aytu BioPharma Adamas Pharmaceuticals Corvus Pharmaceuticals Annexon Aligos Therapeutics Oculis ABIVAX Société Anonyme Astria Therapeutics BioVie (NASDAQ:BIVI) and Tyme Technologies (NASDAQ:TYME) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk. Is BIVI or TYME more profitable? Tyme Technologies' return on equity of -28.30% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets BioVieN/A -259.71% -125.68% Tyme Technologies N/A -28.30%-26.21% Does the MarketBeat Community believe in BIVI or TYME? Tyme Technologies received 185 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 65.58% of users gave Tyme Technologies an outperform vote while only 65.38% of users gave BioVie an outperform vote. CompanyUnderperformOutperformBioVieOutperform Votes1765.38% Underperform Votes934.62% Tyme TechnologiesOutperform Votes20265.58% Underperform Votes10634.42% Do analysts prefer BIVI or TYME? BioVie currently has a consensus price target of $4.00, indicating a potential upside of 44.40%. Given BioVie's higher probable upside, equities analysts clearly believe BioVie is more favorable than Tyme Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Tyme Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has higher valuation and earnings, BIVI or TYME? Tyme Technologies is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioVieN/AN/A-$32.12M-$13.70-0.20Tyme TechnologiesN/AN/A-$23.63M-$0.14-2.22 Does the media prefer BIVI or TYME? In the previous week, BioVie had 5 more articles in the media than Tyme Technologies. MarketBeat recorded 7 mentions for BioVie and 2 mentions for Tyme Technologies. Tyme Technologies' average media sentiment score of 0.44 beat BioVie's score of 0.42 indicating that Tyme Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tyme Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, BIVI or TYME? BioVie has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Tyme Technologies has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Do insiders and institutionals believe in BIVI or TYME? 4.6% of BioVie shares are held by institutional investors. Comparatively, 16.7% of Tyme Technologies shares are held by institutional investors. 4.0% of BioVie shares are held by insiders. Comparatively, 16.9% of Tyme Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryTyme Technologies beats BioVie on 10 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioViePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.84M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.209.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book1.095.324.665.02Net Income-$32.12M$153.56M$119.06M$225.46M7 Day Performance-3.15%0.11%0.80%0.37%1 Month Performance132.77%15.22%5.65%3.57%1 Year Performance-38.17%41.14%36.76%29.44% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie2.5665 of 5 stars$2.77+1.1%$4.00+44.4%-39.8%$25.84MN/A-0.2010Gap DownTYMETyme TechnologiesN/A$0.31flatN/A+0.0%$53.51MN/A-2.2217Gap DownHigh Trading VolumeENLVEnlivex Therapeutics3.3974 of 5 stars$1.48+0.7%$6.00+305.4%+2.4%$31.69MN/A-1.2570News CoverageAYTUAytu BioPharma1.0503 of 5 stars$2.08-3.7%N/A-28.2%$12.44M$81.00M-0.73160Short Interest ↓Positive NewsGap UpADMSAdamas PharmaceuticalsN/A$8.22flatN/AN/A$376.37M$74.46M-4.84138Analyst ForecastCRVSCorvus Pharmaceuticals1.5974 of 5 stars$8.64+4.0%$10.83+25.4%+671.2%$540.44MN/A-19.2030Upcoming EarningsAnalyst DowngradeShort Interest ↑High Trading VolumeANNXAnnexon1.4361 of 5 stars$7.57+2.3%$15.80+108.7%+203.3%$699.57MN/A-6.1560ALGSAligos Therapeutics4.6858 of 5 stars$8.87+5.6%$75.00+745.5%-49.1%$692.84M$7.97M-0.4390Upcoming EarningsHigh Trading VolumeOCSOculis1.9668 of 5 stars$17.05+7.9%$29.20+71.3%+96.5%$690.59M$980,000.00-8.882Gap DownHigh Trading VolumeABVXABIVAX Société Anonyme3.3503 of 5 stars$10.69+3.8%$36.50+241.4%+5.2%$672.71MN/A0.0061Positive NewsATXSAstria Therapeutics1.6912 of 5 stars$12.10+5.5%$25.20+108.3%+137.8%$664.45MN/A-5.2630 Related Companies and Tools Related Companies Tyme Technologies Competitors Enlivex Therapeutics Competitors Aytu BioPharma Competitors Adamas Pharmaceuticals Competitors Corvus Pharmaceuticals Competitors Annexon Competitors Aligos Therapeutics Competitors Oculis Competitors ABIVAX Société Anonyme Competitors Astria Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIVI) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
